Gain Therapeutics News

Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress

TipRanksApr 26 00:15

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)

TipRanksApr 25 18:30

Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy

By Chris Wack Gain Therapeutics shares rose after the company said it saw positive results from an early study of its potential Parkinson's Disease therapy. Shares were up 8% to $3.65 in early tradi

WSJApr 24 21:53

Gain Therapeutics Reports Results From Single Ascending Dose Part Of Phase 1 Clinical Trial Of GT-02287, Novel GCase-Targeting Small Molecule Therapy For GBA1 Parkinson's Disease

GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability profile and the appropriate range o

BenzingaApr 24 21:26

Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target

Oppenheimer analyst Hartaj Singh maintains Gain Therapeutics (NASDAQ:GANX) with a Outperform and maintains $9 price target.

BenzingaApr 23 20:21

Oppenheimer Remains a Buy on Gain Therapeutics (GANX)

TipRanksApr 23 19:45

Here's Why Gain Therapeutics (GANX) Could Be Great Choice for a Bottom Fisher

Yahoo FinanceApr 17 21:55

Insiders Are Piling Into These 10 Healthcare Stocks in 2024

Yahoo FinanceApr 11 03:30

Gain Therapeutics Welcomes New CFO Gene Mack

TipRanksApr 9 04:32

Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX

Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX

Dow JonesApr 8 21:26

Gain Therapeutics Bolsters Management Team With the Appointment of Gene Mack as Chief Financial Officer

Gain Therapeutics, Inc. (Nasdaq: GANX) today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.

GlobeNewswireApr 8 21:25

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int

BenzingaApr 2 19:39

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)

Yahoo FinanceApr 2 07:01

NVCR, SBNY and VITL Are Among After Hour Movers

Seeking AlphaApr 2 05:08

Gain Therapeutics(GANX.US) Director Buys US$115.77K in Common Stock

$Gain Therapeutics(GANX.US)$ Director Riley Jeffrey Scott purchased 30,000 shares of Common Stock on Mar 28, 2024 at an average price of $3.859 for a total value of $115.77K.Source: Announcement What

Futu NewsApr 2 04:41

Gain Therapeutics Gets New Chief Medical Officer

Seeking AlphaApr 1 22:29

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.

BenzingaApr 1 19:15

Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson's Treatment and Solid Financial Outlook

Gain Therapeutics (GANX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $9.00 price target.

TipRanksApr 1 18:18

Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson's Drug Candidate GT-02287

TipRanksMar 28 01:25

Gain Therapeutics Price Target Maintained With a $6.00/Share by Chardan Capital

Gain Therapeutics Price Target Maintained With a $6.00/Share by Chardan Capital

Dow JonesMar 27 16:47